RecruitingNCT06944587

A New Clinical Pathway for Personalized Management of Borderline Resectable and Locally Advanced Pancreatic Cancer

A New Clinical Pathway for Personalized Management of Borderline Resectable and Locally Advanced Pancreatic Cancer - Norwegian Pancreatic Cancer Trial-3 (NORPACT 3)

Sponsor

Oslo University Hospital

Enrollment

400 participants

Start Date

Dec 3, 2024

Study Type

OBSERVATIONAL

Conditions

Chemotherapy Effect Locally Advanced Pancreatic Cancer Pancreatectomy Borderline Resectable Pancreatic Cancer

Summary

NORPACT-3 is a nationwide, Norwegian single arm prospective study that evaluates the resectability rates and survival in patients with borderline resectable and locally advanced pancreatic cancer who received primary chemotherapy. Eligible patients are treated with primary chemotherapy possibly followed by surgical exploration and resection. All Norwegian centres performing pancreatic surgery have agreed to collaborate in this trial. The assignment of the medical intervention is not at the discretion of the investigator, but follow the national Norwegian guidelines regarding diagnostic work up, oncological and surgical treatment and follow up. The primary aim is a national resection rate of 50% in BRPC and 15% in LAPC in patients initiating primary chemotherapy, with adequate overall survival and morbidity/mortality (after resection median overall survival of 24 months, 1 year survival 80%, and 5 year survival \>20% + 90 day postoperative mortality ≤5%, 90-day postoperative major morbidity (Clavien Dindo grade 3) ≤40%).

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This study is developing a personalized care pathway for patients with pancreatic cancer that cannot immediately be surgically removed (borderline resectable or locally advanced). It uses chemotherapy and other treatments first, then reassesses whether surgery becomes possible. **You may be eligible if...** - You are over 18 years old - Your pancreatic cancer has been confirmed by biopsy and is classified as borderline resectable or locally advanced (not yet spread to distant organs) - You are considered healthy enough to receive chemotherapy and potentially undergo surgery - You have provided written consent to participate **You may NOT be eligible if...** - Your health condition or performance status makes chemotherapy or surgery too risky - You are pregnant, breastfeeding, or of childbearing age and not using reliable contraception - Your cancer has already spread to distant organs (metastatic) - You have other serious conditions that would interfere with the study Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGChemotherapy

The choice of chemotherapy regimen follows national guidelines, preferably mFOLFIRINOX or gemcitabine-nab-paclitaxel.

DIAGNOSTIC_TESTRadiology

PET/CT is optional. PET/CT will be offered as a part of the diagnostic work up at baseline and one additional scan after a minimum of two months of chemotherapy.

PROCEDUREPancreatectomy

Surgery is scheduled within 4 weeks after the last neoadjuvant infusion. Resection will be performed as a standard or pylorus-preserving pancreatoduodenectomy (PD), distal pancreatectomy (DP) with splenectomy, or total pancreatectomy (TP) with splenectomy, and with or without venous or arterial resection and reconstruction.

PROCEDUREEndoscopy

Endoscopic ultrasound fine-needle biopsy to establish the diagnosis with histopathology and to obtain an adequate sample for molecular pathology (KRAS status (mutation or wild type), microsatellite instability (MSI)).